Cilastatin sodium (CAS 81129-83-1)
QUICK LINKS
Cilastatin sodium is utilized in biochemical research to investigate the inhibition of human renal enzymes, particularly renal dehydropeptidase-1 (DHP-1). DHP-1 is involved in the metabolic breakdown of certain antibiotics, and cilastatin is studied for its ability to protect these compounds from enzymatic degradation. In experimental applications, researchers use cilastatin sodium to delve into the mechanisms of renal metabolism and to assess how the inhibition of DHP-1 can affect the kinetics and mechanisms of compounds simultaneously administered. This research has broader implications for improving chemical delivery systems and understanding renal clearance. Its use in research extends to the examination of kidney function and the exploration of how endogenous compounds are processed by renal pathways.
Cilastatin sodium (CAS 81129-83-1) References
- A continuous fluorometric assay for leukotriene D4 hydrolase. | White, IJ., et al. 1999. Anal Biochem. 268: 245-51. PMID: 10075814
- Crystal structure of human renal dipeptidase involved in beta-lactam hydrolysis. | Nitanai, Y., et al. 2002. J Mol Biol. 321: 177-84. PMID: 12144777
- Cilastatin protection against cyclosporin A-induced nephrotoxicity: clinical evidence. | Tejedor, A., et al. 2007. Curr Med Res Opin. 23: 505-13. PMID: 17355732
- Cilastatin attenuates cisplatin-induced proximal tubular cell damage. | Camano, S., et al. 2010. J Pharmacol Exp Ther. 334: 419-29. PMID: 20435919
- Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia. | Zilberberg, MD., et al. 2010. Surg Infect (Larchmt). 11: 409-17. PMID: 20666580
- A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. | Jia, B., et al. 2010. Chemotherapy. 56: 285-90. PMID: 20714145
- Cilastatin-insulin interaction in the rat. | Tompkins, GC., et al. 1989. Drug Metab Dispos. 17: 54-7. PMID: 2566470
- Lipid imaging for visualizing cilastatin amelioration of cisplatin-induced nephrotoxicity. | Moreno-Gordaliza, E., et al. 2018. J Lipid Res. 59: 1561-1574. PMID: 30049708
- FKBP51, AmotL2 and IQGAP1 Involvement in Cilastatin Prevention of Cisplatin-Induced Tubular Nephrotoxicity in Rats. | González-Fernández, R., et al. 2022. Cells. 11: PMID: 35563891
- The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterial metallo-beta-lactamase enzyme CphA. | Keynan, S., et al. 1995. Antimicrob Agents Chemother. 39: 1629-31. PMID: 7492120
- Aerosolization of imipenem/cilastatin prevents pseudomonas-induced acute lung injury. | Hashimoto, S., et al. 1996. J Antimicrob Chemother. 38: 809-18. PMID: 8961050
- Dipeptidase inhibitor and epithelial removal potentiate leukotriene D4-induced human tracheal smooth muscle contraction. | Yamaya, M., et al. 1998. Respir Physiol. 111: 101-9. PMID: 9496476
- Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. | Nakamura, T., et al. 1998. Pharm Res. 15: 734-8. PMID: 9619782
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cilastatin sodium, 10 mg | sc-201312 | 10 mg | $285.00 | |||
Cilastatin sodium, 50 mg | sc-201312A | 50 mg | $715.00 |